We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+54.86%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$1.56B
AUM Growth
+$837M
Cap. Flow
+$618M
Cap. Flow %
39.64%
Top 10 Hldgs %
44.99%
Holding
85
New
33
Increased
20
Reduced
4
Closed
28

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$94.1M
2
BAX icon
Baxter International
BAX
+$69.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$46.6M
4
ARVN icon
Arvinas
ARVN
+$45.7M
5
IMMU
Immunomedics Inc
IMMU
+$41.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$49.1M
2
MRK icon
Merck
MRK
+$37.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$25.5M
4
CAH icon
Cardinal Health
CAH
+$24.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.67%
2 Miscellaneous 1.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$451B
$152M 9.72%
1,545,400
+1,068,400
+224% +$94.1M
REGN icon
2
Regeneron Pharmaceuticals
REGN
$81.8B
$82.4M 5.28%
132,100
+82,100
+164% +$46.6M
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$80.8M 5.18%
1,104,500
+564,500
+105% +$30M
BAX icon
4
Baxter International
BAX
$13.5B
$69M 4.42%
+800,900
New +$69.8M
IMMU
5
DELISTED
Immunomedics Inc
IMMU
$67.7M 4.34%
1,911,300
+1,418,300
+288% +$41.5M
EXEL icon
6
Exelixis
EXEL
$13.5B
$64M 4.1%
2,694,070
+1,608,070
+148% +$37.3M
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
$57M 3.65%
507,700
+347,700
+217% +$36.9M
HOLX
8
DELISTED
Hologic
HOLX
$46.6M 2.99%
+817,200
New +$40.1M
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$42.6M 2.73%
250,900
-329,100
-57% -$49.1M
AUPH icon
10
Aurinia Pharmaceuticals
AUPH
$2.17B
$40.2M 2.58%
2,474,599
+1,292,599
+109% +$20.7M
MNTA
11
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$38.3M 2.45%
1,150,000
+370,000
+47% +$11.8M
CCXI
12
DELISTED
ChemoCentryx, Inc.
CCXI
$37.2M 2.38%
645,800
+409,800
+174% +$22.3M
ARVN icon
13
Arvinas
ARVN
$600M
$36.1M 2.32%
+1,076,900
New +$45.7M
AXSM icon
14
Axsome Therapeutics
AXSM
$10.4B
$33.3M 2.14%
404,900
+207,900
+106% +$16M
KDMN
15
DELISTED
Kadmon Holdings, Inc.
KDMN
$32.9M 2.11%
6,426,700
+3,598,700
+127% +$16.1M
PRNB
16
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$32.8M 2.1%
+548,500
New +$33.9M
ZNTL icon
17
Zentalis Pharmaceuticals
ZNTL
$360M
$32.4M 2.08%
+674,487
New +$25.9M
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$29.8M 1.91%
536,200
+203,200
+61% +$8.69M
ESPR
19
DELISTED
Esperion Therapeutics
ESPR
$28.7M 1.84%
559,700
+354,700
+173% +$14.8M
AVTR icon
20
Avantor
AVTR
$9.86B
$27.4M 1.76%
+1,612,000
New +$26.2M
VIR icon
21
Vir Biotechnology
VIR
$1.83B
$25.4M 1.63%
+620,600
New +$20.8M
MRSN
22
DELISTED
Mersana Therapeutics
MRSN
$25M 1.6%
+42,784
New +$14.6M
DVAX
23
DELISTED
Dynavax Technologies
DVAX
$23.7M 1.52%
2,674,154
-1,149,846
-30% -$5.81M
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.74B
$22.6M 1.45%
+1,527,400
New +$23.3M
NBIX icon
25
Neurocrine Biosciences
NBIX
$15.7B
$22.6M 1.45%
185,100
+87,100
+89% +$9.63M
1
2 3 4

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2020 Portfolio in Review

As of Q2 2020, Avidity Partners Management held 85 positions worth $1.56B, up 116% from $724M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Avidity Partners Management deployed $618M of net new capital in Q2 2020, opening 33 new positions and adding to 20 existing holdings. Its largest new stake was Baxter International: 800,900 shares worth $69M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $49.1M trimmed.

  • Avidity Partners Management's largest Q2 2020 buy was Baxter International: 800,900 shares worth $69M.
  • Avidity Partners Management added most to AbbVie in Q2 2020, an estimated $94.1M increase.
  • Avidity Partners Management's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $49.1M.
  • Avidity Partners Management fully exited Merck in Q2 2020, selling an estimated $37.9M.
  • Avidity Partners Management's ten largest holdings make up 45% of its $1.56B portfolio in Q2 2020.
  • Avidity Partners Management opened 33 new positions and closed 28 in Q2 2020.
  • Avidity Partners Management's portfolio value rose 116% quarter-over-quarter to $1.56B.

Based on Avidity Partners Management's 13F filing for Q2 2020, filed 14 Aug 2020.